Vanguard Group’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Vanguard Group’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,005,419	Closed	-$300K	–	4625
2023 Q2	$300K	Sell	1,005,419 -460,108	-31%	-$139K	﹤0.01%	4238
2023 Q1	$634K	Buy	1,465,527 +83,976	+6%	+$64.5K	﹤0.01%	4051
2022 Q4	$1.63M	Buy	1,381,551 +176,115	+15%	+$287K	﹤0.01%	3739
2022 Q3	$2.8M	Buy	1,205,436 +274,020	+29%	+$717K	﹤0.01%	3609
2022 Q2	$2.06M	Sell	931,416 -549,356	-37%	-$3.81M	﹤0.01%	3795
2022 Q1	$14.3M	Buy	+1,480,772	New	+$13.3M	﹤0.01%	2960

Vanguard Group's GRNA Position: Q3 2023 in Review

Vanguard Group sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 1,005,419 shares — an estimated $300K sold.

Vanguard Group first reported a position in GRNA in Q1 2022 and held it in 6 quarters. The position peaked at $14.3M in Q1 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

Vanguard Group reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
Vanguard Group sold 1,005,419 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $300K.
Vanguard Group first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q1 2022 and held it in 6 quarters.
Vanguard Group's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $14.3M in Q1 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.